ATE520032T1 - Differentielle cytokinexpression bei einer menschlichen krebserkrankung - Google Patents

Differentielle cytokinexpression bei einer menschlichen krebserkrankung

Info

Publication number
ATE520032T1
ATE520032T1 AT07764767T AT07764767T ATE520032T1 AT E520032 T1 ATE520032 T1 AT E520032T1 AT 07764767 T AT07764767 T AT 07764767T AT 07764767 T AT07764767 T AT 07764767T AT E520032 T1 ATE520032 T1 AT E520032T1
Authority
AT
Austria
Prior art keywords
human cancer
cytokine expression
differential cytokine
differential
expression
Prior art date
Application number
AT07764767T
Other languages
German (de)
English (en)
Inventor
Giorgio Stassi
Christian Gieffers
Oliver Hill
Meinolf Thiemann
Matilde Todaro
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of ATE520032T1 publication Critical patent/ATE520032T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT07764767T 2006-06-21 2007-06-21 Differentielle cytokinexpression bei einer menschlichen krebserkrankung ATE520032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
ATE520032T1 true ATE520032T1 (de) 2011-08-15

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07764767T ATE520032T1 (de) 2006-06-21 2007-06-21 Differentielle cytokinexpression bei einer menschlichen krebserkrankung

Country Status (12)

Country Link
US (1) US20090324616A1 (enExample)
EP (1) EP2041576B1 (enExample)
JP (1) JP2010514409A (enExample)
CN (1) CN101529253A (enExample)
AT (1) ATE520032T1 (enExample)
AU (1) AU2007263265A1 (enExample)
BR (1) BRPI0713484A2 (enExample)
CA (1) CA2656379A1 (enExample)
DK (1) DK2041576T3 (enExample)
ES (1) ES2371287T3 (enExample)
RU (1) RU2009101783A (enExample)
WO (1) WO2007147600A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004691A1 (en) * 2006-03-22 2008-12-24 Apogenix GmbH Antibody specific for human il-4 for the treament of cancer
CA2656135A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in cancer therapy
CA2878992C (en) * 2012-07-18 2020-09-22 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CA3003133C (en) * 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
MX393612B (es) 2015-08-11 2025-03-24 Calidi Biotherapeutics Nevada Inc Vacuna contra viruela para tratamiento del cancer.
EP3389696B1 (en) 2015-12-17 2024-11-27 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
WO2017177148A1 (en) 2016-04-07 2017-10-12 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN110402393A (zh) * 2016-11-24 2019-11-01 休伯特保健公司 疾病诊断的组合物
AU2018327225A1 (en) * 2017-09-06 2020-02-27 Fred Hutchinson Cancer Center Strep-tag specific chimeric receptors and uses thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
HU222041B1 (hu) 1993-09-07 2003-04-28 Smithkline Beecham Corporation Az IL4 által kőzvetített rendellenességek kezelésére használható rekombináns 1L4 antitestek, eljárás ezek előállítására, alkalmazására és az őket tartalmazó gyógyszerkészítmények
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
ATE195003T1 (de) * 1994-07-05 2000-08-15 Steeno Res Group As Immunomodulatoren
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
US20040023337A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AU2005307831A1 (en) * 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
EP2004691A1 (en) * 2006-03-22 2008-12-24 Apogenix GmbH Antibody specific for human il-4 for the treament of cancer
CA2656135A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in cancer therapy

Also Published As

Publication number Publication date
DK2041576T3 (da) 2011-12-05
BRPI0713484A2 (pt) 2012-11-06
ES2371287T3 (es) 2011-12-29
WO2007147600A2 (en) 2007-12-27
JP2010514409A (ja) 2010-05-06
CA2656379A1 (en) 2007-12-27
AU2007263265A1 (en) 2007-12-27
US20090324616A1 (en) 2009-12-31
RU2009101783A (ru) 2010-07-27
EP2041576A2 (en) 2009-04-01
WO2007147600A3 (en) 2008-04-10
CN101529253A (zh) 2009-09-09
EP2041576B1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
GB2566371A (en) Methods and systems for collecting spirometry data
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
GB2478065A (en) Method and systems for personalized action plans
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2009026657A8 (en) Flavonoid ppar agonists
MY159551A (en) High affinity human antibodies to human protease-activated receptor-2
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
ATE554396T1 (de) Diagnose- und therapiewerkzeuge für krankheiten, die die gefässfunktion verändern
WO2012145535A3 (en) Animal model of human cancer and methods of use
DE602005003570D1 (de) Rohr- und universalkupplung für die zufuhr von zahnmedizinischen oder chirurgischen instrumenteen
MX2007006355A (es) Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico.
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
EP2148934A4 (en) MATRIX MARKER MODEL AND METHOD FOR THE TEST AND TREATMENT OF ARTHRITIS AND RELATED DISEASES
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
BR112012030051A2 (pt) índice de saúde oral
MX2009011388A (es) Inhibidores de polimerasa y su uso para el tratamiento de tumores.
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties